Therapure said that it will apply its experience and knowledge in cell culture and in the design and development of scaled-up biologic manufacturing processes to advance the initial R&D conducted by Induce. The technology is a result of over 10 years of R&D by the founders of Induce in the areas of bone regeneration and the development of growth factor containing bone grafts, added Therapure.
Thomas Wellner, president and CEO of Therapure, said: “Induce’s technology is a tremendous example of the creativity and innovation that exists in Ontario. We are very pleased that they have chosen Therapure Biopharma as their partner for the further development of this important new technology and we look forward to working with them to bring this product to a global market.”